Multi-stakeholder paediatric oncology strategy workshop (cancers with anaplastic lymphoma kinase aberrations)

Date:
30/01/2017 to 31/01/2017
Location: European Medicines Agency, London, UK
The aim of the European Medicines Agency / ACCELERATE platform's workshop is to review unmet therapeutic needs of children with certain types of cancer and opportunities for targeted paediatric development of innovative anti-cancer medicines. The workshop brings together stakeholders from patient organisations, academia, pharmaceutical industry and regulators. The types of cancers that discussed during the workshop include soft tissue and lymphoid and embryonal neoplasms such as inflammatory myofibroblastic tumour, rhabdomyosarcoma, anaplastic large cell lymphoma and neuroblastoma. Important biological aberrations such as of the anaplastic lymphoma kinase (ALK) occur across these diverse cancers, albeit in small numbers of patients, and represent challenges to address the therapeutic needs of affect paediatric patients.

How useful was this page?

Add your rating